公开(公告)号：US20240240156A1

公开(公告)日：2024-07-18

申请号：US18510297

申请日：2023-11-15

Applicant: Genentech, Inc.

Inventor： Amy Shen ,  Gavin Christian Barnard ,  Shuet Ming Yip

IPC: C12N5/071 ,  C07K16/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/85

CPC classification number: C12N5/0682 ,  C07K16/00 ,  C12N9/22 ,  C12N15/111 ,  C12N15/85 ,  C07K2317/622 ,  C12N2310/20 ,  C12N2840/002

Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins where the TI host cells are also subjected to transposon-mediated genomic integration of one or more exogenous nucleic acids, as well as methods of producing and using said combined transposon-mediated genomic integration and TI host cells.

公开(公告)号：US20240228606A1

公开(公告)日：2024-07-11

申请号：US18612141

申请日：2024-03-21

Applicant: GENENTECH, INC.

Inventor： ChinYu LIN ,  Theodore A. OMACHI ,  Ryan P. OWEN ,  Karl YEN ,  Yanan ZHENG ,  Kendra DEBUSK

IPC: C07K16/24 ,  A61K9/00 ,  A61K9/19 ,  A61K31/573 ,  A61K39/00 ,  A61K39/395 ,  A61P17/00

CPC classification number: C07K16/244 ,  A61K9/0014 ,  A61K9/0024 ,  A61K9/19 ,  A61K31/573 ,  A61K39/3955 ,  A61P17/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76

Abstract: Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists.

公开(公告)号：US12030926B2

公开(公告)日：2024-07-09

申请号：US17171962

申请日：2021-02-09

Applicant: Genentech, Inc.

Inventor： Justin Scheer ,  Whitney Shatz ,  Domingos Ng

IPC: C07K16/00 ,  C07K16/46 ,  C12N15/79 ,  C12N15/90

CPC classification number: C07K16/00 ,  C07K16/468 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/53 ,  C12N15/79 ,  C12N15/907

Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.

公开(公告)号：US20240207398A1

公开(公告)日：2024-06-27

申请号：US18423520

申请日：2024-01-26

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Qingyuan LIU ,  Anila TAHIRI ,  Zhao ZHANG ,  Edward Namserk CHA

IPC: A61K39/395 ,  A61K31/282 ,  A61K31/513 ,  A61K31/7068 ,  A61K38/17

CPC classification number: A61K39/3955 ,  A61K31/282 ,  A61K31/513 ,  A61K31/7068 ,  A61K38/1774

Abstract: The invention provides methods and compositions for use in treating cancer, e.g., gastric cancer (e.g., a gastric carcinoma (GC) or a gastroesophageal junction carcinoma (GEJC) (e.g., inoperable, locally advanced, metastatic, or advanced GC or GEJC)) or rectal cancer (e.g., locally advanced rectal cancer (LARC)) in a subject, for example, by administering to the subject a treatment regimen that includes an anti-TIGIT antagonist antibody (e.g., tiragolumab) in combination with a PD-1 axis binding antagonist (e.g., atezolizumab). The treatment regimen may be administered with chemotherapy or following a neoadjuvant chemotherapy regimen. Also provided are compositions (e.g., compositions comprising a PD-1 axis binding antagonist (e.g., atezolizumab) and/or an anti-TIGIT antagonist antibody (e.g., tiragolumab), including pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating cancer, e.g., gastric cancer (e.g., a GC or a GEJC (e.g., inoperable, locally advanced, metastatic, or advanced GC or GEJC)) or rectal cancer (e.g., LARC) in a subject.

公开(公告)号：US20240203101A1

公开(公告)日：2024-06-20

申请号：US18536174

申请日：2023-12-11

Applicant: Genentech, Inc.

Inventor： Miao ZHANG ,  Nagamurali K. MOVVA ,  Mahdi ABBASPOUR TEHRANI

IPC: G06V10/774 ,  G06T7/00 ,  G06V10/82

CPC classification number: G06V10/774 ,  G06T7/0012 ,  G06V10/82 ,  G06T2207/20104 ,  G06T2207/30041 ,  G06V2201/03

Abstract: Systems and methods for annotating medical images using an artificial intelligence (AI)-enabled workflow are disclosed herein. In some example embodiments, an image of a sample may be labeled using an annotation generated by a neural network The annotation may represent a feature in the image. In some instances, the labeled image may be reviewed by laypersons and/or experts for accuracy and/or completeness, and the labeled image may be updated based on the review to generate an annotated image.

公开(公告)号：US20240200146A1

公开(公告)日：2024-06-20

申请号：US18516552

申请日：2023-11-21

Applicant: Genentech, Inc.

Inventor： Christiaan Nicolaas Klijn ,  Shiva Malek ,  Ivana Yen

IPC: C12Q1/6886 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).

公开(公告)号：US20240199594A1

公开(公告)日：2024-06-20

申请号：US18365392

申请日：2023-08-04

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle BRAUN ,  Emily HANAN ,  Steven T. Staben ,  Robert Andrew HEALD ,  Calum MACLEOD ,  Richard ELLIOTT

IPC: C07D413/14 ,  A61K31/553 ,  C07D267/08 ,  C07D498/04

CPC classification number: C07D413/14 ,  A61K31/553 ,  C07D267/08 ,  C07D498/04

Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:




or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

公开(公告)号：US12007398B2

公开(公告)日：2024-06-11

申请号：US16874550

申请日：2020-05-14

Applicant: Genentech, Inc.

Inventor： Kendall Carey

IPC: A61K38/00 ,  C07K16/28 ,  G01N33/50 ,  G01N33/567 ,  G01N33/68

CPC classification number: G01N33/6854 ,  C07K16/2809 ,  C07K16/2887 ,  G01N33/505 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/92 ,  G01N33/6845

Abstract: The present invention provides a cell-based assay for identifying and/or quantifying anti-CD3 homodimers in a composition comprising a T cell-dependent Bispecific antibody (TDB). In some aspects, the invention T cells comprising a T cell activation responsive reporter are contacted with the TDB to detect the presence of anti-CD3 homodimers. Compositions of reporter T cells and kits are also contemplated.

公开(公告)号：US20240183860A1

公开(公告)日：2024-06-06

申请号：US18493957

申请日：2023-10-25

Applicant: Genentech, Inc.

Inventor： Jian Mehr-Dean Payandeh ,  Patrick C. Reid ,  Christian Nathaniel Cunningham ,  Evan Green ,  Christopher Koth ,  Vishal Verma

IPC: G01N33/68 ,  A61K38/00 ,  C07K7/56

CPC classification number: G01N33/6845 ,  C07K7/56 ,  G01N33/6872 ,  A61K38/00

Abstract: The present disclosure relates to chimeric ABC transporter proteins and methods of screening for molecules that bind to the periplasmic, extracellular, and/or luminal face of an ABC transporter protein using the chimeric ABC transporters. For example, in some embodiments, screening methods involve providing a chimeric ABC transporter in which one or more regions of the periplasmic, extracellular, and/or luminal face of the ABC transporter are substituted with one or more equivalent regions of the periplasmic, extracellular, and/or luminal face of a different ABC transporter and selecting for molecules that bind to the ABC transporter but do not bind to the chimeric ABC transporter. The disclosure also relates to molecules that bind to the periplasmic, extracellular, and/or luminal face of an ABC transporter protein, for example, identified in such screens.

公开(公告)号：US11999749B2

公开(公告)日：2024-06-04

申请号：US17852227

申请日：2022-06-28

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Francis Gosselin ,  Stefan G. Koenig ,  Eduardo V. Mercado-Marin ,  Andreas Stumpf ,  Daniel Zell ,  Haiming Zhang ,  Stephan Bachmann ,  Diane E. Carrera ,  Michael E. Dalziel ,  Yonghui Ge ,  Jie Zhang ,  Raphael Bigler ,  Laure Elizabeth Simone Finet ,  Regis Jean Georges Mondiere ,  Yuki Nakagawa

IPC: C07D495/04

CPC classification number: C07D495/04

Abstract: A manufacturing process to a bis-mesylate salt 1b of the pan-RAF inhibitor 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide. The process features a number of efficient key reactions, including a robust and scalable Pd-catalyzed carbonylation reaction to generate thienopyrimidine 2 and a highly chemoselective Pt/V/C-catalyzed nitro group reduction to access penultimate intermediate 7. The final amide coupling of 7 and 2 was accomplished by a mild and safe protocol employing N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate (TCFH) as the coupling reagent, to produce a 1:1 adduct of the freebase and THF. The adduct afforded compound 1b with excellent yield, purity, and form stability on a multikilogram production scale after reaction with MsOH and recrystallization. The methods are able to produce a compound having upwards of 95% purity.